Evidence map›Paper›PMID 38931218›Full record

ArticleNutrients2024

Tolerance of Infants Fed a Hydrolyzed Rice Infant Formula with 2'-Fucosyllactose (2'-FL) Human Milk Oligosaccharide (HMO).

Carlett Ramirez-Farias, Jeffery S Oliver, Jane Schlezinger, John T Stutts

Abstract readMulticenter Study
In one paragraph

Article in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Carlett Ramirez-FariasScientific & Medical Affairs, Abbott Nutrition, Columbus, OH 43219, USA.ORCID 0000-0002-6796-239X
Jeffery S OliverScientific & Medical Affairs, Abbott Nutrition, Columbus, OH 43219, USA.
Jane SchlezingerScientific & Medical Affairs, Abbott Nutrition, Columbus, OH 43219, USA.
John T StuttsScientific & Medical Affairs, Abbott Nutrition, Columbus, OH 43219, USA.

Funding

Abbott Nutrition AL49
6 · The paper itself

Abstract

backgroundThe purpose of this research was to assess the growth, tolerance, and compliance outcomes associated with the consumption of a hydrolyzed rice infant formula (HRF) enriched with 2'-Fucosyllactose (2'-FL) a Human Milk Oligosaccharide (HMO), and nucleotides in an intended population of infants.

methodsThis was a non-randomized single-group, multicenter study. The study formula was a hypoallergenic HRF with 2'-FL, Docosahexaenoic acid (DHA), Arachidonic acid (ARA), and nucleotides. Infants 0-90 days of age who were formula fed and experiencing persistent feeding intolerance symptoms, symptoms of suspected food protein (milk and/or soy) allergy, or other conditions where an extensively hydrolyzed infant formula was deemed an appropriate feeding option were recruited by pediatricians from their local populations. The primary outcome was maintenance of weight-for-age z-score. Weight, length, head circumference, formula intake, tolerance measures, clinical symptoms and questionnaires were collected. Thirty-three infants were enrolled, and 27 completed the study, on study product.

resultsWeight-for-age z-scores of infants showed a statistically significant improvement from Visit 1 to Visit 4 (

conclusionsHRF with 2'-FL HMO was safe, well tolerated, and supported weight gain in infants with suspected cow's milk allergy or persistent feeding intolerance.

Indexed as

Infant FormulaMilk, HumanOligosaccharidesOryzaTrisaccharidesFemaleHumansInfantInfant, NewbornInfant Nutritional Physiological PhenomenaMale2'-fucosyllactoseOligosaccharidesTrisaccharides2′-FLcow’s milk allergyHMOhuman milk oligosaccharideshydrolyzed rice formula

Identifiers

PMID38931218
PMCPMC11206301

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.